SOURCE: IsoRay, Inc.

IsoRay, Inc.

August 10, 2015 08:30 ET

Isoray, Inc. Announces Appointment of PCG Advisory Group as Investor, Public and Digital Communications Agency of Record

RICHLAND, WA and NEW YORK, NY--(Marketwired - Aug 10, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it has appointed PCG Advisory Group (PCG) as its investor, public and digital communications agency of record.

IsoRay's CEO Dwight Babcock commented, "We had the opportunity to meet with Jeff Ramson and his team at PCG and we were impressed by their overall knowledge of our business and the competitive landscape we face. In addition, PCG has extensive experience building out digital and social media for their clients. We look forward to working together to refine our digital footprint."

Jeff Ramson, Founder and CEO of PCG, stated, "IsoRay has unique, cutting edge technology that can fill unmet clinical needs in brain, lung, head and neck, prostate and gynecologic cancers. We look forward to partnering with IsoRay and refining the Company's messages for investors, the media and social media audiences."

IsoRay's various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life. Cesium-131 is now being used for the treatment of a wide array of cancers throughout the body, including brain, lung, head and neck, chest wall, prostate and gynecologic cancers.

About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting Join us on Facebook/Isoray. Follow us on Twitter @Isoray.


Founded in 2008, PCG Advisory Group is dedicated to the delivery of top tier capital markets advisory services, strategic and tactical digital and social media communications, as well as cutting edge media and public relations, for public and privately held companies. The team at PCG has extensive experience with life sciences and healthcare, high technology, financial services and emerging growth companies from around the globe.

Safe Harbor Statement

Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether PCG and IsoRay will be successful in refining IsoRay's digital footprint, and its investor, media and social media messages, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information